| First-line treatment, CR = 10/85 (12%) | N (m.d.) | 85 (56) | % |
| Anthracycline-based chemotherapy | 35 | 41 | |
| Vinblastine monotherapy | 10 | 12 | |
| MEK or BRAF inhibitors | 9 | 11 | |
| Surgery | 6 | 8 | |
| ICE | 3 | 4 | |
| Temozolomide-based chemotherapy | 3 | 4 | |
| Cladribine | 3 | 4 | |
| Surgery and radiotherapy | 2 | 2 | |
| Surgery and anthracycline-based chemotherapy | 1 | 1 | |
| Radiotherapy and anthracycline-based chemotherapy | 1 | 1 | |
| Anthracycline-based chemotherapy and MEK or BRAF inhibitors | 1 | 1 | |
| Other treatments | 11 | 13 | |
| Second-line treatment, CR = 6/52 (12%) | N (m.d.) | 52 (89) | |
| MEK or BRAF inhibitors | 15 | 29 | |
| Anthracycline-based chemotherapy | 8 | 15 | |
| Vinblastine monotherapy | 5 | 10 | |
| Cladribine | 4 | 8 | |
| Radiotherapy | 4 | 9 | |
| Allogeneic stem cell transplantation | 2 | 4 | |
| ICE | 2 | 4 | |
| Surgery | 1 | 2 | |
| Anti–PD-1 | 1 | 2 | |
| Temozolomide-based chemotherapy | 1 | 2 | |
| Other treatments | 9 | 17 | |
| Third-line treatment | N (m.d.) | 31 (110) | |
| MEK or BRAF inhibitors | 4 | 13 | |
| Temozolomide-based chemotherapy | 4 | 13 | |
| Spindle poison–based chemotherapy | 3 | 10 | |
| Cladribine | 2 | 6 | |
| ICE and anti–PD-1 | 2 | 6 | |
| Anthracycline-based chemotherapy | 2 | 6 | |
| ICE | 2 | 6 | |
| Surgery | 1 | 3 | |
| Anti–PD-1 | 1 | 3 | |
| Other treatments | 10 | 32 |
| First-line treatment, CR = 10/85 (12%) | N (m.d.) | 85 (56) | % |
| Anthracycline-based chemotherapy | 35 | 41 | |
| Vinblastine monotherapy | 10 | 12 | |
| MEK or BRAF inhibitors | 9 | 11 | |
| Surgery | 6 | 8 | |
| ICE | 3 | 4 | |
| Temozolomide-based chemotherapy | 3 | 4 | |
| Cladribine | 3 | 4 | |
| Surgery and radiotherapy | 2 | 2 | |
| Surgery and anthracycline-based chemotherapy | 1 | 1 | |
| Radiotherapy and anthracycline-based chemotherapy | 1 | 1 | |
| Anthracycline-based chemotherapy and MEK or BRAF inhibitors | 1 | 1 | |
| Other treatments | 11 | 13 | |
| Second-line treatment, CR = 6/52 (12%) | N (m.d.) | 52 (89) | |
| MEK or BRAF inhibitors | 15 | 29 | |
| Anthracycline-based chemotherapy | 8 | 15 | |
| Vinblastine monotherapy | 5 | 10 | |
| Cladribine | 4 | 8 | |
| Radiotherapy | 4 | 9 | |
| Allogeneic stem cell transplantation | 2 | 4 | |
| ICE | 2 | 4 | |
| Surgery | 1 | 2 | |
| Anti–PD-1 | 1 | 2 | |
| Temozolomide-based chemotherapy | 1 | 2 | |
| Other treatments | 9 | 17 | |
| Third-line treatment | N (m.d.) | 31 (110) | |
| MEK or BRAF inhibitors | 4 | 13 | |
| Temozolomide-based chemotherapy | 4 | 13 | |
| Spindle poison–based chemotherapy | 3 | 10 | |
| Cladribine | 2 | 6 | |
| ICE and anti–PD-1 | 2 | 6 | |
| Anthracycline-based chemotherapy | 2 | 6 | |
| ICE | 2 | 6 | |
| Surgery | 1 | 3 | |
| Anti–PD-1 | 1 | 3 | |
| Other treatments | 10 | 32 |
ICE, ifosfamide-carboplatin-etoposide; m.d., missing data; PD-1, programmed cell death protein 1.